Showing results for Ben Middelkamp

Cristian Lasagna-Reeves, PhD received the prestigious 2024 Rainwater Prize for Innovative Early-Career Scientist. Lasagna-Reeves was presented the award at the Alzheimer’s Association’s Tau2024 Global Conference on March 25, 2024 in Washington, D.C.

A group of Indiana University School of Medicine trainees in the Medical Neuroscience Graduate Program at Stark Neurosciences Research Institute is teaming up with fellow scientists from the Eugene and Marilyn Glick Eye Institute to host a lecture about the science behind solar eclipses and their impact on ocular health.

LEADS, led by Liana Apostolova, MD, has received $78 million in National Institute of Aging (NIA) funding since it launched in 2018. It's also the largest National Institutes of Health grant at IU School of Medicine in 2023 at $13.9 million.

Led by Wei Wu, PhD, assistant professor of neurological surgery and a primary member of Stark Neurosciences Research Institute, the researchers discovered a connection between the reprogramming of NG2 glial cells and robust axonal regeneration after spinal cord injury.  

Three Indiana University School of Medicine researchers each received National Institutes of Health grant funding to study under-explored mechanisms and connections in the brain using animal models. Through their investigations, they hope to discover therapeutic targets to treat health conditions, including obesity, anxiety and alcohol use disorder. The faculty investigators are members of the addiction research interest group at Stark Neurosciences Research Institute.

Glick Eye Institute researchers Arupratan Das, PhD, Padmanabhan Pattabiraman, PhD, Weiming Mao, PhD and Tasneem Sharma, PhD—also members of the ocular neurobiology research interest group at Stark Neurosciences Research Institute— are exploring ways to prevent and treat the disease.

Neurologists at Indiana University School of Medicine are among the first clinicians in the nation to administer a groundbreaking gene-based therapy for patients living with a rare form of amyotrophic lateral sclerosis (ALS).

For nearly a decade, lecanemab has been tested in clinical trials at IU School of Medicine—the newly FDA-approved drug is now being administered to patient at IU Health. The drug targets the removal of amyloid plaques in the brain—a hallmark of Alzheimer’s disease.

The Alzheimer’s Association recently named Kate Foley, PhD, postdoctoral fellow in the Department of Neurology at Indiana University School of Medicine, as the inaugural Dr. Mel Perelman Fellow for Alzheimer’s Research.

This research fellowship, named in honor of the late Mel Perelman, PhD, a former executive of Eli Lilly and Company, will be awarded annually to an IU School of Medicine researcher who has been vetted and selected by the Alzheimer’s Association’s Medical and Scientific Advisory Group to receive a research grant.